GE MEDICAL SYSTEMS

GE HealthCare to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP) by purchasing Sumitomo Chemical's 50% stake, expected to close in early 2025. NMP specializes in radiopharmaceuticals for SPECT and PET imaging, used in neurology, cardiology, and oncology. GE HealthCare's PDx segment aims to strengthen precision care in Asia, leveraging NMP's expertise and scale.

GE HealthCare Technologies Inc. launched Sonic DL for 3D, expanding its imaging technology to include brain, spine, orthopedic, body scans, and heart exams, aiming to maintain a 12x speed boost and reduce scan times by up to 86%.

GE HealthCare to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP) from Sumitomo Chemical, enhancing patient access to next-generation radiopharmaceuticals and positioning NMP as a partner for global innovators in Japan and Asia. The transaction bolsters GE HealthCare's Pharmaceutical Diagnostics segment and demonstrates its commitment to shaping the future of Molecular Imaging.

GE HealthCare to showcase over 40 innovations at RSNA 2024, including AI-enabled technologies like Clarify DL, nCommand Lite, enhanced True PACS, and CareIntellect for Oncology. Notable launches include MINItrace Magni cyclotron, Omni Legend, and Flyrcado PET MPI agent for CAD detection.

GE HealthCare to acquire remaining 50% stake in Nihon Medi-Physics (NMP) from Sumitomo Chemical, aiming for full ownership. NMP, with 2023 revenues of 28.2B JPY (~183M USD), specializes in radiopharmaceuticals for SPECT and PET imaging. The deal, expected to close in early 2025, will enhance GE HealthCare's Pharmaceutical Diagnostics segment and improve patient access to next-gen radiopharmaceuticals in Japan and Asia.

The global MRI compatible patient monitoring systems market is expected to grow from USD 3,851.4 million in 2022 to USD 5,958.6 million by 2032, driven by technological advancements, expanding MRI applications, and rising healthcare expenditure. Key trends include technological innovations, strategic collaborations, and new product launches. While safety concerns and regulatory challenges restrain growth, opportunities exist in emerging markets and diverse applications.

GE HealthCare to showcase over 40 AI-enabled innovations at RSNA 2024, focusing on enhancing patient care and operational efficiencies. Key products include Clarify DL, nCommand Lite, True PACS, MR Max 3™, and Vscan Air SL. Collaboration with RadNet aims to advance AI in imaging. Not all products are globally available due to regulatory constraints.

DeepHealth, a RadNet subsidiary, received expanded FDA 510(k) clearance for its SmartMammo Dx AI algorithm, now compatible with GE HealthCare's Senographe Pristina mammography systems, enhancing breast cancer screening programs.

DeepHealth’s AI algorithm, SmartMammo Dx, receives expanded FDA clearance for compatibility with GE HealthCare’s Senographe Pristina mammography systems, enhancing breast cancer detection and expanding access to high-quality screening.